NEW YORK (GenomeWeb News) – Sony DADC Austria and Singulex today announced a supply agreement for the design and manufacture of customized detection vessels by Sony DADC BioSciences for Singulex's Sgx Clarity System.
Currently under development, Sgx Clarity is an ultrasensitive in vitro diagnostic platform that uses Singulex's proprietary single molecule counting technology. The fully automated system is expected to be able to detect low abundance biomarkers at femtograms per milliliter levels, the companies said.
Sony is manufacturing the detection vessel "as a one-piece, molded microtiter plate that has high optical transparency, high purity, and low fluorescence, all critical properties required for achieving the ultrasensitivity of the Sgx Clarity System," the partners said, adding that the vessel is manufactured in Sony's clean-room environment under ISO 13485.
Last week, Singulex announced a deal with Tecan to co-develop the Sgx Clarity System. With that deal and today's agreement, Singulex is poised "to move forward toward commercialization and clinical testing of the Sgx Clarity System," Sony and Singulex said.
The partners did not disclose the financial and other terms of the multiyear deal.